Cargando…

Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose

The complex development of type 2 diabetes (T2D) creates challenges for studying the progression and treatment of the disease in animal models. A newly developed rat model of diabetes, the Zucker Diabetic Sprague Dawley (ZDSD) rat, closely parallels the progression of T2D in humans. Here, we examine...

Descripción completa

Detalles Bibliográficos
Autores principales: Weninger, Savanna N., Ding, Angela, Browne, Elizabeth N., Frost, Morgan L., Schiro, Gabriele, Laubitz, Daniel, Duca, Frank A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220957/
https://www.ncbi.nlm.nih.gov/pubmed/37233701
http://dx.doi.org/10.3390/metabo13050660
_version_ 1785049341701914624
author Weninger, Savanna N.
Ding, Angela
Browne, Elizabeth N.
Frost, Morgan L.
Schiro, Gabriele
Laubitz, Daniel
Duca, Frank A.
author_facet Weninger, Savanna N.
Ding, Angela
Browne, Elizabeth N.
Frost, Morgan L.
Schiro, Gabriele
Laubitz, Daniel
Duca, Frank A.
author_sort Weninger, Savanna N.
collection PubMed
description The complex development of type 2 diabetes (T2D) creates challenges for studying the progression and treatment of the disease in animal models. A newly developed rat model of diabetes, the Zucker Diabetic Sprague Dawley (ZDSD) rat, closely parallels the progression of T2D in humans. Here, we examine the progression of T2D and associated changes in the gut microbiota in male ZDSD rats and test whether the model can be used to examine the efficacy of potential therapeutics such as prebiotics, specifically oligofructose, that target the gut microbiota. Bodyweight, adiposity, and fed/fasting blood glucose and insulin were recorded over the course of the study. Glucose and insulin tolerance tests were performed, and feces collected at 8, 16, and 24 weeks of age for short-chain fatty acids and microbiota analysis using 16s rRNA gene sequencing. At the end of 24 weeks of age, half of the rats were supplemented with 10% oligofructose and tests were repeated. We observed a transition from healthy/nondiabetic to prediabetic and overtly diabetic states, via worsened insulin and glucose tolerance and significant increases in fed/fasted glucose, followed by a significant decrease in circulating insulin. Acetate and propionate levels were significantly increased in the overt diabetic state compared to healthy and prediabetic. Microbiota analysis demonstrated alterations in the gut microbiota with shifts in alpha and beta diversity as well as alterations in specific bacterial genera in healthy compared to prediabetic and diabetic states. Oligofructose treatment improved glucose tolerance and shifted the cecal microbiota of the ZDSD rats during late-stage diabetes. These findings underscore the translational potential of ZDSD rats as a model of T2D and highlight potential gut bacteria that could impact the development of the disease or serve as a biomarker for T2D. Additionally, oligofructose treatment was able to moderately improve glucose homeostasis.
format Online
Article
Text
id pubmed-10220957
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102209572023-05-28 Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose Weninger, Savanna N. Ding, Angela Browne, Elizabeth N. Frost, Morgan L. Schiro, Gabriele Laubitz, Daniel Duca, Frank A. Metabolites Article The complex development of type 2 diabetes (T2D) creates challenges for studying the progression and treatment of the disease in animal models. A newly developed rat model of diabetes, the Zucker Diabetic Sprague Dawley (ZDSD) rat, closely parallels the progression of T2D in humans. Here, we examine the progression of T2D and associated changes in the gut microbiota in male ZDSD rats and test whether the model can be used to examine the efficacy of potential therapeutics such as prebiotics, specifically oligofructose, that target the gut microbiota. Bodyweight, adiposity, and fed/fasting blood glucose and insulin were recorded over the course of the study. Glucose and insulin tolerance tests were performed, and feces collected at 8, 16, and 24 weeks of age for short-chain fatty acids and microbiota analysis using 16s rRNA gene sequencing. At the end of 24 weeks of age, half of the rats were supplemented with 10% oligofructose and tests were repeated. We observed a transition from healthy/nondiabetic to prediabetic and overtly diabetic states, via worsened insulin and glucose tolerance and significant increases in fed/fasted glucose, followed by a significant decrease in circulating insulin. Acetate and propionate levels were significantly increased in the overt diabetic state compared to healthy and prediabetic. Microbiota analysis demonstrated alterations in the gut microbiota with shifts in alpha and beta diversity as well as alterations in specific bacterial genera in healthy compared to prediabetic and diabetic states. Oligofructose treatment improved glucose tolerance and shifted the cecal microbiota of the ZDSD rats during late-stage diabetes. These findings underscore the translational potential of ZDSD rats as a model of T2D and highlight potential gut bacteria that could impact the development of the disease or serve as a biomarker for T2D. Additionally, oligofructose treatment was able to moderately improve glucose homeostasis. MDPI 2023-05-16 /pmc/articles/PMC10220957/ /pubmed/37233701 http://dx.doi.org/10.3390/metabo13050660 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Weninger, Savanna N.
Ding, Angela
Browne, Elizabeth N.
Frost, Morgan L.
Schiro, Gabriele
Laubitz, Daniel
Duca, Frank A.
Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose
title Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose
title_full Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose
title_fullStr Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose
title_full_unstemmed Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose
title_short Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose
title_sort longitudinal characterization of the gut microbiota in the diabetic zdsd rat model and therapeutic potential of oligofructose
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220957/
https://www.ncbi.nlm.nih.gov/pubmed/37233701
http://dx.doi.org/10.3390/metabo13050660
work_keys_str_mv AT weningersavannan longitudinalcharacterizationofthegutmicrobiotainthediabeticzdsdratmodelandtherapeuticpotentialofoligofructose
AT dingangela longitudinalcharacterizationofthegutmicrobiotainthediabeticzdsdratmodelandtherapeuticpotentialofoligofructose
AT browneelizabethn longitudinalcharacterizationofthegutmicrobiotainthediabeticzdsdratmodelandtherapeuticpotentialofoligofructose
AT frostmorganl longitudinalcharacterizationofthegutmicrobiotainthediabeticzdsdratmodelandtherapeuticpotentialofoligofructose
AT schirogabriele longitudinalcharacterizationofthegutmicrobiotainthediabeticzdsdratmodelandtherapeuticpotentialofoligofructose
AT laubitzdaniel longitudinalcharacterizationofthegutmicrobiotainthediabeticzdsdratmodelandtherapeuticpotentialofoligofructose
AT ducafranka longitudinalcharacterizationofthegutmicrobiotainthediabeticzdsdratmodelandtherapeuticpotentialofoligofructose